Daniel N Tavares

US Patent:

7538195, May 26, 2009

Filed:

Jun 14, 2002

Appl. No.:

10/170390

Inventors:

Rajeeva Singh - Cambridge MA, US
Daniel J. Tavares - Natick MA, US
Nancy E. Dagdigian - Acton MA, US

Assignee:

Immunogen Inc. - Waltham MA

International Classification:

C12P 21/08
C07K 16/00
A61K 39/395
A61K 49/00
C07H 21/04
G01N 33/574

US Classification:

5303873, 424 91, 4241331, 4241411, 4241431, 4241551, 4241781, 4241811, 4241831, 435 696, 435 7021, 5303881, 53038822, 5303888, 5303917

Abstract:

Antibodies, humanized antibodies, resurfaced antibodies, antibody fragments, derivatized antibodies, and conjugates of these molecules with cytotoxic agents, which specifically bind to and inhibit insulin-like growth factor-I receptor, antagonize the effects of IGF-I and are substantially devoid of agonist activity toward the insulin-like growth factor-I receptor. These molecules can be conjugated to cytotoxic agents for use in the treatment of tumors that express elevated levels of IGF-I receptor, such as breast cancer, colon cancer, lung cancer, ovarian carcinoma, synovial sarcoma and pancreatic cancer. These molecules can also be labeled for in vitro and in vivo diagnostic uses, such as in the diagnosis and imaging of tumors that express elevated levels of IGF-I receptor.

US Patent:

7557189, Jul 7, 2009

Filed:

Nov 5, 2003

Appl. No.:

10/700632

Inventors:

Mary G. Hoffee - Brookline MA, US
Daniel Tavares - Natick MA, US
Robert J. Lutz - Wayland MA, US

Assignee:

Immunogen Inc. - Waltham MA

International Classification:

C12P 21/08
C07K 16/00
A61K 39/395
C12P 21/04
C12N 5/06
C07H 21/04

US Classification:

5303871, 4241301, 4241331, 4241411, 4241431, 4241551, 4241811, 4241831, 435 696, 435 7021, 435449, 5303873, 5303881, 53038822, 5303888, 5303913, 5303917

Abstract:

The present invention relates to antibodies that bind CD33. More particularly, the invention relates to anti-CD33 antibodies, fragments and homologues of these antibodies, humanized and resurfaced versions of these antibodies, functional equivalents and improved versions of these antibodies, immunoconjugates and compositions comprising these antibodies, and the uses of same in diagnostic, research and therapeutic applications. The invention also relates to a polynucleotide encoding these antibodies, vectors comprising the polynucleotides, host cells transformed with polynucleotides and methods of producing these antibodies.

US Patent:

7834155, Nov 16, 2010

Filed:

Aug 29, 2005

Appl. No.:

11/213046

Inventors:

Gillian Payne - Waban MA, US
Philip Chun - Malden MA, US
Daniel J. Tavares - Natick MA, US

Assignee:

Immunogen Inc. - Waltham MA

International Classification:

C12P 21/08
C07K 16/00
A61K 39/395
C12P 21/04
C07H 21/04

US Classification:

5303873, 5303881, 5303888, 53038885, 5303917, 4241331, 4241411, 4241551, 4241561, 435 696, 435 7021

Abstract:

Cytotoxic conjugates comprising a cell binding agent and a cytotoxic agent, therapeutic compositions comprising the conjugate, methods for using the conjugates in the inhibition of cell growth and the treatment of disease, and a kit comprising the cytotoxic conjugate are disclosed are all embodiments of the invention. In particular, the cell binding agent is a monoclonal antibody, and epitope-binding fragments thereof, that recognizes and binds the CA6 glycotope. The present invention is also directed to humanized or resurfaced versions of DS6, an anti-CA6 murine monoclonal antibody, and epitope-binding fragments thereof.

US Patent:

7985842, Jul 26, 2011

Filed:

Nov 24, 2008

Appl. No.:

12/276586

Inventors:

Rajeeva Singh - Cambridge MA, US
Daniel J. Tavares - Natick MA, US
Nancy E. Dagdigian - Acton MA, US

Assignee:

Immunogen Inc. - Waltham MA

International Classification:

C12P 21/08
C07K 16/00
A61K 39/395
A61K 49/00
C07H 21/04
G01N 33/574

US Classification:

5303873, 424 91, 4241331, 4241411, 4241431, 4241551, 4241781, 4241811, 4241831, 435 696, 435 7021, 5303881, 53038822, 5303888, 5303917

Abstract:

Antibodies, humanized antibodies, resurfaced antibodies, antibody fragments, derivatized antibodies, and conjugates of these molecules with cytotoxic agents, which specifically bind to and inhibit insulin-like growth factor-I receptor, antagonize the effects of IGF-I and are substantially devoid of agonist activity toward the insulin-like growth factor-I receptor. These molecules can be conjugated to cytotoxic agents for use in the treatment of tumors that express elevated levels of IGF-I receptor, such as breast cancer, colon cancer, lung cancer, ovarian carcinoma, synovial sarcoma and pancreatic cancer. These molecules can also be labeled for in vitro and in vivo diagnostic uses, such as in the diagnosis and imaging of tumors that express elevated levels of IGF-I receptor.

US Patent:

8034904, Oct 11, 2011

Filed:

Dec 8, 2003

Appl. No.:

10/729441

Inventors:

Rajeeva Singh - Cambridge MA, US
Daniel J. Tavares - Natick MA, US
Nancy E. Dagdigian - Acton MA, US

Assignee:

Immunogen Inc. - Waltham MA

International Classification:

C12P 21/08

US Classification:

5303873, 5303881, 53038822, 5303888, 5303917, 424 91, 4241331, 4241411, 4241431, 4241551, 4241781, 4241811

Abstract:

Antibodies, humanized antibodies, resurfaced antibodies, antibody fragments, derivatized antibodies, and conjugates of these molecules with cytotoxic agents, which specifically bind to and inhibit insulin-like growth factor-I receptor, antagonize the effects of IGF-I and are substantially devoid of agonist activity toward the insulin-like growth factor-I receptor. These molecules can be conjugated to cytotoxic agents for use in the treatment of tumors that express elevated levels of IGF-I receptor, such as breast cancer, colon cancer, lung cancer, ovarian carcinoma, synovial sarcoma and pancreatic cancer. These molecules can also be labeled for in vitro and in vivo diagnostic uses, such as in the diagnosis and imaging of tumors that express elevated levels of IGF-I receptor.

US Patent:

8119787, Feb 21, 2012

Filed:

Jun 12, 2009

Appl. No.:

12/483543

Inventors:

Mary G. Hoffee - Brookline MA, US
Daniel Tavares - Natick MA, US
Robert J. Lutz - Wayland MA, US

Assignee:

Immunogen, Inc. - Waltham MA

International Classification:

C07H 21/04
C12P 20/04
C12N 15/00
C12N 5/07
C12N 5/16

US Classification:

536 2353, 435 696, 4353201, 435326

Abstract:

The present invention relates to antibodies that bind CD33. More particularly, the invention relates to anti-CD33 antibodies, fragments and homologues of these antibodies, humanized and resurfaced versions of these antibodies, functional equivalents and improved versions of these antibodies, immunoconjugates and compositions comprising these antibodies, and the uses of same in diagnostic, research and therapeutic applications. The invention also relates to a polynucleotide encoding these antibodies, vectors comprising the polynucleotides, host cells transformed with polynucleotides and methods of producing these antibodies.

US Patent:

8153765, Apr 10, 2012

Filed:

Oct 16, 2007

Appl. No.:

12/441466

Inventors:

Peter U. Park - Somerville MA, US
Laura M. Bartle - Arlington MA, US
Anna Skaletskaya - Cambridge MA, US
Daniel Tavares - Natick MA, US
Jutta Deckert - Lexington MA, US
Vincent Mikol - Paris, FR
Veronique Blanc - Paris, FR

Assignee:

Sanof Aventis - Paris

International Classification:

C12P 21/08

US Classification:

5303873, 530350, 5303871, 5303882, 5303887, 5303888, 5303891, 5303896, 5303897, 5303913, 5303917, 435334

Abstract:

Antibodies, humanized antibodies, resurfaced antibodies, antibody fragments, derivatized antibodies, and conjugates of same with cytotoxic agents, which specifically bind to CD38, are capable of killing CD38 cells by apoptosis, antibody-dependent cell-mediated cytotoxicity (ADCC), and/or complement-dependent cytotoxicity (CDC). Said antibodies and fragments thereof may be used in the treatment of tumors that express CD38 protein, such as multiple myeloma, chronic lymphocytic leukemia, chronic myelogenous leukemia, acute myelogenous leukemia, or acute lymphocytic leukemia, or the treatment of autoimmune and inflammatory diseases such as systemic lupus, rheumatoid arthritis, multiple sclerosis, erythematosus, and asthma. Said derivatized antibodies may be used in the diagnosis and imaging of tumors that express elevated levels of CD38. Also provided are cytotoxic conjugates comprising a cell binding agent and a cytotoxic agent, therapeutic compositions comprising the conjugate, methods for using the conjugates in the inhibition of cell growth and the treatment of disease, and a kit comprising the cytotoxic conjugate.

US Patent:

8268617, Sep 18, 2012

Filed:

Aug 26, 2009

Appl. No.:

12/547543

Inventors:

Rajeeva Singh - Cambridge MA, US
Daniel J. Tavares - Natick MA, US
Nancy E. Dagdigian - Acton MA, US

Assignee:

ImmunoGen, Inc. - Waltham MA

International Classification:

C12N 5/16
C12N 5/07
C12N 15/113
C07H 21/04
C07K 16/28

US Classification:

435334, 536 235, 536 2353, 435 696, 435 701, 435 702, 435 7021, 435449, 435326, 435327, 435330, 4353201, 5303871, 5303873, 5303881

Abstract:

DNAs, vectors, host cells and genetic constructs of antibodies, humanized antibodies, resurfaced antibodies, antibody fragments, derivatized antibodies, and conjugates of these molecules with cytotoxic agents, which specifically bind to and inhibit insulin-like growth factor-I receptor, antagonize the effects of IGF-I and are substantially devoid of agonist activity toward the insulin-like growth factor-I receptor. These molecules can be conjugated to cytotoxic agents for use in the treatment of tumors that express elevated levels of IGF-I receptor, such as breast cancer, colon cancer, lung cancer, ovarian carcinoma, synovial sarcoma and pancreatic cancer. These molecules can also be labeled for in vitro and in vivo diagnostic uses, such as in the diagnosis and imaging of tumors that express elevated levels of IGF-I receptor.